

IFW

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE.

In re Application of:

Cham et al.

Serial No. 10/601,656

Filed: June 20, 2003

)
)
)
)
)
)

Art Unit: 1623

Examiner: Not yet assigned


For: A Method of Treating and Preventing Infectious Diseases Via Creation of a
Modified Particle With Immunogenic Properties

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with
the United States Postal Service as first class mail in an envelope
addressed to: Mail Stop Amendment, Commissioner for Patents,
P.O. Box 1450, Alexandria, VA 22313-1450, on August 16, 2004



Matthew L. Collins

Sir:


The citation of information on the attached Form PTO/SB/08 is made pursuant to
37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy of each Non-U.S. Patent cited item is enclosed.

The citation of this information does not constitute an admission of priority or that
any cited item is available as a reference, or a waiver of any right the applicant may have under
applicable statutes, Rules of Practice in patent cases, or otherwise.

Respectfully submitted,


John K. McDonald, Ph.D.
Reg. No. 42,830

KILPATRICK STOCKTON LLP
1100 Peachtree Street, Suite 2800
Atlanta, Georgia 30309-4530
(404) 815-6500
Our Docket: 13131-0310 (44378/282108)

Substitute for Form 1449/A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number		10/601,656	
		Filing Date		June 20, 2003	
		First Named Inventor		Cham	
		Group Art Unit		1623	
		Examiner Name		Not yet Assigned	
Sheet	1	of	9	Attorney Docket Number 13131-0310 (44378/282108)	

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	1	3,647,624		Evenson	03-07-1972	
	2	3,958,939		Jones	05-25-1976	
	3	3,983,008		Shinozaki et al.	09-28-1976	
	4	3,989,466		Pan	11-02-1976	
	5	4,025,423		Stonner et al.	05-24-1977	
	6	4,103,685		Lupien et al.	08-01-1978	
	7	4,124,509		Iijima et al.	11-07-1978	
	8	4,234,317		Lucas et al.	11-18-1980	
	9	4,235,602		Meyer et al.	11-25-1980	
	10	4,258,010		Rozsa et al.	03-24-1981	
	11	4,350,156		Malchesky et al.	09-21-1982	
	12	4,391,711		Jackson et al.	07-05-1983	
	13	4,399,217		Holmquist et al.	08-16-1983	
	14	4,402,940		Nose et al.	09-16-1983	
	15	4,435,289		Breslau	03-06-1984	
	16	4,463,988		Bouck et al.	08-07-1984	
	17	4,645,512		Johns	02-24-1987	
	18	4,647,280		Maaskant et al.	03-03-1987	
	19	4,648,974		Roskopf et al.	03-10-1987	
	20	4,668,398		Silvis	05-26-1987	
	21	4,671,909		Torobin	09-09-1987	
	22	4,676,905		Nagao et al.	06-30-1987	
	23	4,677,057		Curtiss et al.	06-30-1987	
	24	4,680,320		Uku et al.	07-14-1987	
	25	4,696,670		Ohnishi et al.	09-29-1987	
	26	4,775,483		Mookerjea et al.	10-04-1988	
	27	4,832,034		Pizziconi et al.	05-23-1989	
	28	4,836,928		Aoyagi et al.	06-06-1989	
	29	4,879,037		Utzinger	11-07-1989	
	30	4,908,354		Seidel et al.	03-13-1990	
	31	4,909,942		Sato et al.	03-20-1990	
	32	4,935,204		Seidel et al.	06-19-1990	
	33	4,966,709		Nose et al.	10-30-1990	
	34	4,970,144		Fareed et al.	11-13-1990	
	35	5,026,479		Bikson et al.	06-25-1991	
	36	5,080,796		Nose et al.	01-14-1992	
	37	5,089,602		Isliker et al.	02-18-1992	
	38	5,112,956		Tang et al.	05-12-1992	
	39	5,126,240		Curtiss	03-30-1992	
	40	5,128,318		Levine et al.	07-07-1992	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/601,656
		Filing Date	June 20, 2003
		First Named Inventor	Cham
		Group Art Unit	1623
		Examiner Name	Not yet Assigned
Sheet 2	of 9	Attorney Docket Number	13131-0310 (44378/282108)

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	41	5,152,743		Gorsuch et al.	10-06-1992	
	42	5,187,010		Parham et al.	02-16-1993	
	43	5,203,778		Boehringer	04-20-1993	
	44	5,211,850		Shettigar et al.	05-18-1993	
	45	5,236,644		Parham et al.	08-17-1993	
	46	5,258,149		Parham et al.	11-02-1993	
	47	5,279,540		Davidson	01-18-1994	
	48	5,301,694		Raymond et al.	04-12-1994	
	49	5,354,262		Boehringer et al.	10-11-1994	
	50	5,391,143		Kensey	02-21-1995	
	51	5,393,429		Nakayama et al.	02-28-1995	
	52	5,401,415		Rauh et al.	03-28-1995	
	53	5,401,466		Foltz et al.	03-28-1995	
	54	5,418,061		Parham et al.	05-23-1995	
	55	5,424,068		Filip	06-13-1995	
	56	5,476,715		Otto	12-19-1995	
	57	5,496,637		Parham et al.	03-05-1996	
	58	5,523,096		Okarma et al.	06-04-1996	
	59	5,634,893		Rishton	06-03-1997	
	60	5,637,224		Sirkar et al.	06-10-1997	
	61	5,652,339		Lerch et al.	07-29-1997	
	62	5,679,260		Boos et al.	10-21-1997	
	63	5,707,673		Prevost et al.	01-13-1998	
	64	5,753,227		Strahilevitz	05-19-1998	
	65	5,855,782		Falkenhagen et al.	01-05-1999	
	66	5,858,238		McRea et al.	01-12-1999	
	67	5,919,369		Ash	07-06-1999	
	68	5,948,441		Lenk et al.	09-09-1999	
	69	5,962,322		Kozarsky et al.	10-05-1999	
	70	5,980,478		Gorsuch et al.	11-09-1999	
	71	6,004,925		Dasseux et al.	12-21-1999	
	72	6,022,333		Kensev	02-28-2000	
	73	6,037,323		Dasseux et al.	03-14-2000	
	74	6,037,458		Hirai et al.	03-14-2000	
	75	6,039,946		Strahilevitz	03-21-2000	
	76	6,046,166		Dasseux et al.	04-04-2000	
	77	6,080,778		Yankner et al.	06-27-2000	
	78	6,127,370		Smith et al.	10-03-2000	
	79	6,139,746		Kopf	10-31-2000	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/601,656
Filing Date	June 20, 2003
First Named Inventor	Cham
Group Art Unit	1623
Examiner Name	Not yet Assigned
Attorney Docket Number	13131-0310 (44378/282108)

Sheet	3	of	9
-------	---	----	---

U.S. PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Number	10/601,656
Filing Date	June 20, 2003
First Named Inventor	Cham
Group Art Unit	1623
Examiner Name	Not yet Assigned
Attorney Docket Number	13131-0310 (44378/282108)

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/601,656		
		Filing Date	June 20, 2003		
		First Named Inventor	Cham		
		Group Art Unit	1623		
		Examiner Name	Not yet Assigned		
Sheet	5	of	9	Attorney Docket Number	13131-0310 (44378/282108)

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	118	Albouz, et al., Ann. Biol. Clin., Extraction of Plasma Lipids Preserving Antigenic Properties of Proteins and Allowing Quantitation of Gangliosides by Neuraminic Acid Determination, 37, 287-290. (abstract only) (1979)	
	119	Andre et al., Journal of Virology, Characterization of Low- and Very-Low-Density Hepatitis C Virus RNA-Containing Particles, 76 (14), 6919-6928. (July 2002)	
	120	Asztalos et al., Arterioscler. Thromb. Vasc. Biol., Distribution of Apo A-I-Containing HDL Subpopulations in Patients with Coronary Heart Disease, 2670-2676. (December 1, 2000)	
	121	Asztalos et al., Arterioscler. Thromb. Vasc. Biol., Presence and Formation of 'Free Apolipoprotein A-I-Like' Particles in Human Plasma, 15, 1419-1423. (1995)	
	122	Asztalos et al., Arterioscler. Thromb. Vasc. Biol., Role of Free Apolipoprotein A-I in Cholesterol Efflux, 17, 1630-1636. (1997)	
	123	Badimon, et al., Laboratory Investigation, High Density Lipoprotein Plasma Fractions Inhibit Aortic Fatty Streaks in Cholesterol-Fed Rabbits, 60, 455-461. (1989)	
	124	Badimon, et al., J. Clinical Investigation, Regression of Atherosclerotic Lesions by High Density Lipoprotein Plasma Fraction in the Cholesterol-Fed Rabbit, 85, 1234-1241. (1990)	
	125	Barrans et al., Biochimica et Biophysica Acta, Pre- β HDL: Structure and Metabolism, 1300, 73-85. (1996)	
	126	Barres et al., Science, Cholesterol - Making or Breaking the Synapse, 294, 1296/1297. (November 9, 2001)	
	127	Bloom, et al., Clin. Biochem., Quantitation of lipid profiles from isolated serum lipoproteins using small volumes of human serum, 14, 119-125. (abstract only) (June 1981)	
	128	Cham, Clinical Chemistry, Nature of the Interaction Between Low-Density Lipoproteins and Polyanions and Metal Ions, as Exemplified by Heparin and Ca ²⁺ , 22, 1812-1816. (1976)	
	129	Cham, et al., Clinical Chemistry, Changes in Electrophoretic Mobilities of α - and β -Lipoproteins as a Result of Plasma Delipidation, 22, 305-309. (1976)	
	130	Cham, et al., Biochemical and Biophysical Research Communications, Heterogeneity of Lipoprotein B, 103, 196-206. (1981)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/601,656
		Filing Date	June 20, 2003
		First Named Inventor	Cham
		Group Art Unit	1623
		Examiner Name	Not yet Assigned
Sheet 6	of 9	Attorney Docket Number	13131-0310 (44378/282108)

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	131	Cham, et al., Chem. Biol. Interactions, Importance of Apolipoproteins in Lipid Metabolism, 20, 263-277. (1978)	
	132	Cham, et al., J. Biol. Chem., In Vitro Partial Relipidation of Apolipoproteins in Plasma, 251, 6367-6371. (abstract only) (1976)	
	133	Cham, et al., Pharmacol. (Life Sci. Adv.), Lipid Apheresis in an Animal Model Causes Acute Reduction in plasma Lipid Concentrations and Mobilisation of Lipid from Liver and Aorta, 13, 25-32. (1994)	
	134	Cham, et al., J. Clin. Apheresis, Lipid Apheresis in an Animal Model Causes In Vivo Changes in Lipoprotein Electrophoretic Patterns, 11, 61-70. (1996)	
	135	Cham, et al., Clinical Chemistry, Phospholipids in EDTA - Treated Plasma and Serum, 39, 2347-2348. (1993)	
	136	Cham, et al., 59th Congress European Atherosclerosis Society, Nice, France, Rapid Regression of Atherosclerosis by Cholesterol Apheresis - A Newly Developed Technique, 17-21. (abstract only) (May 1992)	
	137	Cham, et al., Clinica Chimica Acta, Rapid, Sensitive Method for the Separation of Free Cholesterol from Ester Cholesterol, 49, 109-113. (1973)	
	138	Collet et al., Journal of Biological Chemistry, Differential Effects of Lecithin and Cholesterol on the Immunoreactivity and Confirmation of Apolipoprotein A-I in High Density Lipoproteins, 266 (14), 9145-9152. (May 15, 1991)	
	139	Cooper, Drugs Aging, Dietary Lipids in the Aetiology of Alzheimer's Disease: Implications for Therapy, 20 (6), 399-418. (abstract only) (2003)	
	140	Cruzado et al., Analytical Biochemistry, Characterization and Quantitation of the Apoproteins of High-Density Lipoprotein by Capillary Electrophoresis, 14 (7), 100-109. (1996)	
	141	Dwivedy, 18th Australian Atherosclerosis Society Conference, Surfers Paradise, Increase of Reverse Cholesterol Transport by Cholesterol Apheresis Regression of Atherosclerosis, 21. (1992)	
	142	Eisenhauer, et al, Klin Wochenschr (KWH), Selective Removal of Low Density Lipoproteins (LDL) by Precipitation at Low pH: First Clinical Application of the HELP System, 65, 161-168. (1987)	
	143	Fang, et al., 18th Australian Atherosclerosis Society Conference, Gold Coast, Australia, In Vivo Rapid Mobilization of Adipose Tissue by Lipid Apheresis - A Newly Developed Technique. (1992)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/601,656
		Filing Date	June 20, 2003
		First Named Inventor	Cham
		Group Art Unit	1623
		Examiner Name	Not yet Assigned
Sheet 7 of 9	Attorney Docket Number	13131-0310 (44378/282108)	

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	144	Golde et al., Drug Discovery Today, Cholesterol Modulation as an Emerging Strategy for the Treatment of Alzheimer's Disease, 6 (20), 1049-1055. (abstract only) (October 15, 2001)	
	145	Hatch et al., Lipoprotein Analysis, Advances in Lipid Research, Practical Methods for Plasma Lipoprotein Analysis, 6, 1-68. (1968)	
	146	Innerarity, et al., Biochemistry, Enhanced Binding by Cultured Human Fibroblasts of Apo-E-Containing Lipoproteins as Compared with Low Density Lipoproteins, 17, 1440-1447. (1978)	
	147	Jackson et al., Biochimica et Biophysica Acta, Isolation and Characterization of the Major Apolipoprotein from Chicken High Density Lipoproteins, 420, 342-349. (1976)	
	148	Koizumi, et al., J. Lipid Research, Behavior of Human Apolipoprotein A-1: Phospho-Lipid and apoHDL: Phospholipid Complexes In Vitro and After Injection into Rabbits, 29, 1405-1415. (1988)	
	149	Kostner, et al., XI Internet Symp. on Drugs Affecting Lipid Metabolism, Italy, Increase of APO A1 Concentration in Hypercholesterolaemic Chickens after Treatment with a Newly Developed Extracorporeal Lipid Elimination. (May 13, 1992)	
	150	Kostner, et al., European Journal of Clinical Investigation, Lecithin-cholesterol acyltransferase activity in Normocholesterolaemic and Hypercholesterolaemic Roosters: Modulation by Lipid Apheresis, 27, 212-218. (May 7, 1997)	
	151	Koudinov et al., Clin Chim Acta, Alzheimer's Amyloid Beta Interaction with Normal Human Plasma High Density Lipoprotein: Association with Apolipoprotein and Lipids, 270 (2), 75-84. (abstract only) (February 23, 1999)	
	152	Koudinov et al., Cell Biol Int., Alzheimer's Soluble Amyloid Beta Protein is Secreted by HepG2 Cells as an Apolipoprotein, 21 (5), 265-71. (abstract only) (May 1997)	
	153	Koudinov et al., Biochem Biophys Res Commun, Biochemical Characterization of Alzheimer's Soluble Amyloid Beta Protein in Human Cerebrospinal Fluid: Association with High Density Lipoproteins, 223 (3), 592-7. (abstract only) (June 25, 1999)	
	154	Koudinov et al., Science, Cholesterol's Role in Synapse Formation, 294, 2213. (November 9, 2001)	
	155	Koudinova et al., Soc. Neuroscience Abstract Viewer and Itinerary Planner, Amyloid Beta, Neural Lipids, Cholesterol and Alzheimer's Disease - Abstract No, 21.10. (2002)	
	156	Lipid Sciences, http://www.lipidsciences.com/technology.html , Lipid Technology, 1-4. (August 25, 2001)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/601,656		
		Filing Date	June 20, 2003		
		First Named Inventor	Cham		
		Group Art Unit	1623		
		Examiner Name	Not yet Assigned		
Sheet	8	of	9	Attorney Docket Number	13131-0310 (44378/282108)

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	157	Lupien, et al., Lancet (LOS), A New Approach to the Management of Familial Hypercholesterolaemia: Removal of Plasma-Cholesterol Based on the Principle of Affinity Chromatography, 1, 1261-1265. (1976)	
	158	Mauch et al., Science, CNS Synaptogenesis Promoted by Glia-Derived Cholesterol, 294, 1354-1357. (November 9, 2001)	
	159	Moya et al., Arteriosclerosis and Thrombosis, A Cell Culture System for Screening Human Serum for Ability to Promote Cellular Cholesterol Efflux, 14 (7), 1056-1065. (July 1994)	
	160	Okazaki et al., Journal of Chromatography, Biomedical Applications, Improved High-Performance Liquid Chromatographic Method for the Determination of Apolipoproteins in Serum High-Density Lipoproteins, 430, 135-142. (1988)	
	161	Refolo et al., Soc. Neuroscience Abstracts, Cholesterol Metabolism: A Potential Target for Alzheimer's Disease Therapy, 27 (2), 1518. (abstract only) (2001)	
	162	Robern et al., Experientia, The Application of Sodium Deoxycholate and Sephacryl-200 for the Delipidation and Separation of High Density Lipoproteins, 38, 437-439. (1982)	
	163	Ryan, et al., Clinical Chemistry, An Improved Extraction Procedure for the Determination of Triglycerides and Cholesterol in Plasma or Serum, 13, 769-772. (1967)	
	164	Scanu et al., Analytical Biochemistry, Solubility in Aqueous Solutions of Ethanol of the Small Molecular Weight Peptides of the Serum Very Low Density and High Density Lipoproteins: Relevance to the Recovery Problem During Delipidation of Serum Lipoproteins, 44, 576-588. (1971)	
	165	Segrest et al., Journal of Biological Chemistry, A Detailed Molecular Belt Model for Apolipoprotein A-I in Discoidal High Density Lipoprotein, 274 (45), 31755-31758. (November 5, 1999)	
	166	Slater, et al., J. of Lipid Research, A Comparison of Delipidated Sera Used in Studies of Sterol Synthesis by Human Mononuclear Leukocytes, 20, 413-416. (1979)	
	167	Slater, et al., Atherosclerosis, The Effect of Delipidated High Density Lipoprotein on Human Leukocyte Sterol Synthesis, 35, 41-49. (1980)	
	168	Thompson, et al., Lancet (LOS), Plasma Exchange in the Management of Homozygous Familial Hypercholesterolaemia, 1, 1208-1211. (1975)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/601,656
		Filing Date	June 20, 2003
		First Named Inventor	Cham
		Group Art Unit	1623
		Examiner Name	Not yet Assigned
Sheet 9	of 9	Attorney Docket Number	13131-0310 (44378/282108)

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	169	Williams, et al., Proc. Natl. Acad. Sci. USA, Low Density Lipoprotein Receptor-Independent Hepatic Uptake of a Synthetic, Cholesterol-Scavenging Lipoprotein: Implications for the Treatment of Receptor-Deficient Atherosclerosis, 85, 242-246. (1988)	
	170	Williams et al., Biochim. Biophys. Act., Uptake of Endogenous Cholesterol by a Synthetic Lipoprotein, 875 (2), 183-194. (February 12, 1986)	
	171	Wong, et al, Journal of Lipid Research, Retention of gangliosides in serum delipidated by diisopropyl ether-1-butanol extraction, 24, 666-669. (1983)	
	172	Wormser, Henry, PSC3110 - Fall Semester 2002, Lipids.	
	173	Yokoyama, et al., Arteriosclerosis, Selective Removal of Low Density Lipoprotein by Plasmapheresis in Familial Hypercholesterolemia, 5, 613-622. (1985)	
	174	Yoshidome et al., Artif Organs, Serum Amyloid A and P Protein Levels are Lowered by Dextran Sulfate Cellulose Low-Density Lipoprotein Apheresis, 22 (2), 144-148. (1998)	
	175	Zhang et al., Journal of Lipid Research, Characterization of phospholipids in a pre-alpha HDL: Selective Phospholipid Efflux with Apolipoprotein A-I, 39, 1601-1607. (1998)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.